Aroa Biosurgery Limited (ARX.AX)
Aroa Biosurgery Limited operates in the Medical - Devices industry of the Healthcare sector, headquartered in Auckland, AU, NZ. The stock last traded at $0.58, up 0.00% on the session, giving a market capitalisation of $202.1M. Its beta of 0.85 implies it has historically moved less than the broad market.
Aroa Biosurgery Limited operates as a regenerative medicine company dedicated to the development, production, and global distribution of medical solutions for wound and tissue repair. The firm innovatively utilizes extracellular matrix (ECM) technology, with its market presence spanning the United States and international territories. Its product line encompasses Endoform Natural and Endoform Antimicrobial Restorative Bioscaffold, tailored for managing both acute and chronic wounds. Additionally, the company offers Myriad Matrix, an engineered ECM device designed for soft tissue repair, reinforcement, and complex wound treatment, along with Myriad Morcells, a powdered version of Myriad Matrix serving similar soft tissue and complex wound applications. Rounding out its offerings are Reinforced Bioscaffolds, a specialized surgical product employed in ventral hernia repair and abdominal wall reconstruction. Founded in 2007, Aroa Biosurgery Limited is headquartered in Auckland, New Zealand.
Aroa Biosurgery Limited is most often compared with the following Healthcare names: